BR112016027897A2 - polipeptídio multimérico, ácido nucleico, vetor de expressão recombinante, célula hospedeira geneticamente modificada, composição, método, e, método de tratamento de uma infecção num indivíduo - Google Patents
polipeptídio multimérico, ácido nucleico, vetor de expressão recombinante, célula hospedeira geneticamente modificada, composição, método, e, método de tratamento de uma infecção num indivíduoInfo
- Publication number
- BR112016027897A2 BR112016027897A2 BR112016027897A BR112016027897A BR112016027897A2 BR 112016027897 A2 BR112016027897 A2 BR 112016027897A2 BR 112016027897 A BR112016027897 A BR 112016027897A BR 112016027897 A BR112016027897 A BR 112016027897A BR 112016027897 A2 BR112016027897 A2 BR 112016027897A2
- Authority
- BR
- Brazil
- Prior art keywords
- infection
- treating
- individual
- nucleic acid
- composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000003259 recombinant expression Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
métodos e composições para inibir ou estimular clonalmente células-t são fornecidos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013715P | 2014-06-18 | 2014-06-18 | |
| US62/013,715 | 2014-06-18 | ||
| PCT/US2015/035777 WO2015195531A2 (en) | 2014-06-18 | 2015-06-15 | Syntac polypeptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016027897A2 true BR112016027897A2 (pt) | 2017-10-24 |
| BR112016027897B1 BR112016027897B1 (pt) | 2024-08-13 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018005937A2 (pt) | conjugados de oligonucleotídeo de afinidade e usos destes | |
| GB2557123A (en) | Modified cells and methods of therapy | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| EA201992001A1 (ru) | Композиции и способы повышения экспрессии генов | |
| MX2022013540A (es) | Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica. | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| BR112016022814A8 (pt) | composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico | |
| MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
| CY1121217T1 (el) | Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων | |
| BR112017023707A2 (pt) | composição, métodos para tratamento de infecções de pele ou mucosas ou dermatite atópica, vetor recombinante, célula hospedeira, e, polipeptídeo recombinante. | |
| BR112016016916A2 (pt) | método de tratamento de angiodema hereditário (hae) | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| DK3362560T3 (da) | Beskyttede dna-templater til genmodificering og forøget homolog rekombination i celler og fremgangsmåder til anvendelse | |
| DK3310909T3 (da) | Sammensætninger og fremgangsmåder til at føre proteiner til specifikke loci i genomet | |
| EP4303314A3 (en) | Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection | |
| BR112019010906A2 (pt) | polinucleotídeo, vetor, adenovírus, composição, célula, polipeptídeo, uso dos mesmos, e, métodos para induzir e para elicitar uma resposta imune e para profilaxia ou tratamento em um indivíduo. | |
| BR112017015567A2 (pt) | proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica | |
| BR112013026929A2 (pt) | composição e método para intensificação de uma resposta imune | |
| BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
| UY34663A (es) | Acido nucleico y proteina recombinante del gen de la endotoxina axmi345, vectores, células, composiciones y métodos para proteger plantas | |
| EA201692254A1 (ru) | Иммуномодулирующие прогениторные (имп) клетки | |
| EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
| BR112017004202A2 (pt) | composições para intensificar respostas imunes e seus usos | |
| BR112013030396A2 (pt) | polipeptídeo, polinucleotídeo, vetor, célula hospedeira, composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina | |
| BR112019005748A2 (pt) | afinidade-conjugados de oligonucleotídeo e usos destes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B25A | Requested transfer of rights approved |
Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE (US) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2015, OBSERVADAS AS CONDICOES LEGAIS |